Top Links

Articles Related to r2

Drug Therapy Problems and Clinical Outcomes Among Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer on Trastuzumab-Based Therapy in a Kenyan Tertiary Health Facility

Breast cancer ranks first among the most commonly diagnosed cancers in Kenyan females and globally. Treatment is challenging because it is a heterogeneous disease with several subtypes. There has been a significant change in the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer subtypes following the introduction and widespread use of HER2 targeted therapies.
View complete article: PDF  |  Full-text

Increased expression of Nppc and Npr2 in ovarian tissues from mice with polycystic ovary syndrome

Weight loss is an efficient therapy for obese polycystic ovary syndrome (PCOS) patients. Here we evaluate the effect of dietary weight reduction on clinical performance in obese PCOS patients. Medical records of fifty obese PCOS patients (age 27 ± 5 years) who had calorie-controlled dietary intervention were reviewed. The patients had a 1200-kcal/day diet until ovulation or for up to three months. Changes in body weight, body mass index (BMI), blood pressure, menstruation, acne, and hirsutusm, serum levels of endocrine hormones and adipocytokines, glucolipid metabolism index and insulin resistance were assessed. Menstrual cycle, ovulation andrelapse in the following six months were also reviewed. All patients had menstrual disorder, 43 had acne, and 26 were hirsute. After weight loss, the BMI decreased from 27.89 ± 3.06 to 25.70 ± 2.42 kg/m2 (p < 0.001). Acne and hirsutusm was improved in 39 and 14 patients, respectively. Regular menstruation was restored in 26 patients and lasted for 3.12 months on average. Endocrine hormones levels, adipocytokines levels, glucolipid metabolism and insulin resistance were shifted toward balance. Weight relapse was seen in 11 patients. No side effects occurred. Dietary intervention in obese PCOS patients can improve relevant clinical problems but weight relapse is an issue
View complete article: PDF  |  Full-text

Recent Advancements Involving Immunoliposomes to Target Breast Cancer

Breast cancer is caused by genetic abnormalities resulting in uncontrolled growth of breast cells, and is the most commonly diagnosed cancer amongst women. The clinical use of liposomal-based drugs to treat solid tumors such as breast cancer has been shown to improve the overall pharmacological properties of otherwise “unencapsulated” cytotoxic agents.
View complete article: PDF  |  Full-text

Advances in the Treatment of Breast Cancer-Emphasis on fertility preservationA Case Report

With the recent advances in breast cancer treatment the 5 year survival rates have increased significantly with overall 20yrs survival in developed countries like USA. With further improvement being designed in the treatment of breast cancers with more and more sophisticated models to study breast cancer in human beings using the modern microfluidic models one expects more and younger breast cancer survivors to be needing fertility treatments. Here we review the modern advances in breast cancer treatments and the need for emphasizing on fertility preservation before starting any chemotherapeutic or other management as recommended by both ASO and ASRM.
View complete article: PDF  |  Full-text

Liquid Biopsy in Advanced Gastric Malignancy and Molecular Targeted Therapy; a Case Report and Update Pertaining Anti HER2-Neu Therapy

Human epidermal growth factor receptor 2 (HER2) is responsible for the pathogenesis and poor outcomes of several types of cancers, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs on the other hand, such as trastuzumab, prolong overall survival and progression-free survival in HER2-positive gastric cancer. The purpose of the case report is to evaluate the impact of delivering trastuzumab in advanced gastric cancer with concomitant HER2 mutation and amplification.
View complete article: PDF  |  Full-text

T2* MRI Correlates with R2 Liver Iron Concentration in Transfusion Dependent Thalassaemia

Despite the introduction of chelation therapy, progressive iron overload continues to complicate management of transfusion dependent thalassaemia. Cardiac arrhythmias and cardiomyopathy are the predominant causes of death, while endocrinopathies and cirrhosis contribute to morbidity and mortality.
View complete article: PDF  |  Full-text

Reduction of Bitterness and Enhancing Palatability of Cetirizine Oral Liquid Dosage Forms by Cyclodextrins

The aim of this manuscript is to study cyclodextrins (CDs) as a potential excipient to suppress bitterness and enhance palatability of pediatric liquid preparations for Cetirizine, an extremely bitter drug. Natural α, β and γ CDs; and β CD derivatives such as hydroxyl propyl (HP), randomly methylated (RM) and sulfobutyl ether (SBE) β-CDs were screened in different molar ratios of 1:1, 1:2 and 1:3 for their inhibition of the extremely bitter taste of Cetirizine using the human gustatory sensation test.
View complete article: PDF  |  Full-text


Editorial Board Members Related to r2

Yun Dai

Associate Professor
Department of Medicine
Virginia Commonwealth University
United States

AMY H. TANG

Associate Professor
Department of Microbiology and Molecular Cell Biology
Eastern Virginia Medical School
United States

Chunying Li

Assistant Professor
Department of Biochemistry and Molecular Biology
Wayne State University School of Medicine
United States
Submit Manuscript


Open Access Journals

View All Journals